FDA
-
-
-
-
-
-
-
AVEO Oncology Reports Second Quarter 2022 Financial Results
-
-
-
-
-
-
-
Actinium Pharma (ATNM) and AVEO Oncology (AVEO) Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
-
-
-
-
-
-
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastati
-
-
-
-
-
-
-
AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference
-
-
-
-
-
-
-
AVEO Oncology (AVEO) Adds Kevin Cullen, M.D. to Board
-
-
-
-
-
-
-
Pre-Open Movers 03/23: (ORMP) (TKAT) (BLFS) Higher; (FREQ) (ANIX) (IONX) Lower (more...)
-
-
-
-
-
-
-
AVEO Oncology (AVEO) to Regain Ex-North American Rights to AV-203
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

